Speaker illustration

Doctor Felix Hofer

Medical University of Vienna, Vienna (Austria)

Member of:

European Society of Cardiology

Fibroblast growth factor-23 is an independent predictor of hospitalization for heart failure and major cardiovascular adverse events in patients undergoing cardiac surgery

Event: ESC Congress 2022

Topic: Biomarkers

Session: Chronic heart failure - Prognosis and prediction of outcome


Influence of diabetes, heart failure, and NT-proBNP on cardiovascular outcomes in patients with atrial fibrillation - Insights from a cohort study of 7,412 patients with extended follow-up

Event: ESC Congress 2021 - The Digital Experience

Topic: Comorbidities

Session: Diabetes and kidney disease in heart failure: how should we treat the terrible triplets?


The prognostic impact of fibroblast growth factor-23 on cardiovascular death after cardiac surgery

Event: ESC Congress 2021 - The Digital Experience

Topic: Biomarkers

Session: Risk Factors and Prevention ePosters


Prognostic impact of left ventricular thrombus resolution after myocardial infarction on cardiovascular events and mortality

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Acute Coronary Syndromes ePosters


This platform is supported by

logo Novo Nordisk